4TECH successfully completes first two implantations of TriCinch Coil tricuspid valve repair system

4TECH Inc., a leader in the field of transcatheter tricuspid valve repair, initiated its U.S. Early Feasibility Study, following receipt of approval from the U.S. Food and Drug Administration (FDA), with the successful first two implantations of the TriCinch™ Coil System at **Piedmont Heart Hospital**, Atlanta, Georgia, by **Dr. Christopher Meduri**, **Dr. Vivek Rajagopal** and **Dr. Mani Vannan**. The study will evaluate the TriCinch Coil System in 15 patients across seven centers in the U.S.

"We are pleased to be the first center in the U.S. to implant the TriCinch Coil System," said **Dr. Christopher Meduri**. *"Both procedures went smoothly, and the device was easy to implant. Having a technology like the TriCinch Coil System in our structural heart toolkit allows us to treat a wide range of patients suffering from tricuspid regurgitation, who are at high risk for open heart surgery, in a safe and simple manner."*

The 4TECH TriCinch Coil System is a simple percutaneous direct annuloplasty device designed to reduce tricuspid regurgitation by means of tricuspid valve (TV) remodeling via a unique nitinol coil anchor that is tensioned by a nitinol stent in the inferior vena cava (IVC).

"This is a major milestone for 4TECH, and I am excited with the progress the team has made," said **Tom Fleming, 4TECH CEO**. *"The TriCinch Coil System is designed to simply target the underlying pathology of annular dilatation. With this device,*

we are committed to helping patients who have very limited treatment options.”

“Through our experience and in collaboration with key physicians, we have built a robust clinical program to evaluate the safety and efficacy of the device,” said **Keith D. Dawkins, MD, 4TECH CMO.** *“I am encouraged by our momentum, and I am confident that we will provide physicians with a novel solution that will benefit patients suffering from TR.”*

The device is being evaluated worldwide with a CE-Trial that has enrollment in both Australia and Europe.

Source:

Accueil